Literature DB >> 33391251

Cleavage of HMGB1 by Proteolytic Enzymes Associated with Inflammatory Conditions.

Agnieszka Sowinska1, Merlin Rensing1, Lena Klevenvall1, Manoj Neog1, Peter Lundbäck1, Helena Erlandsson Harris1.   

Abstract

Extracellular HMGB1 acts as an alarmin in multiple autoimmune diseases. While its release and functions have been extensively studied, there is a substantial lack of knowledge regarding HMGB1 regulation at the site of inflammation. Herein we show that enzymes present in arthritis-affected joints process HMGB1 into smaller peptides in vitro. Gel electrophoresis, Western blotting and mass spectrometry analyses indicate cleavage sites for human neutrophil elastase, cathepsin G, and matrix metalloproteinase 3 within the HMGB1 structure. While human neutrophil elastase and matrix metalloproteinase 3 might alter the affinity of HMGB1 to its receptors by cleaving the acidic C-terminal tail, cathepsin G rapidly and completely degraded the alarmin. Contrary to a previous report we demonstrate that HMGB1 is not a substrate for dipeptidyl peptidase IV. We also provide novel information regarding the presence of these proteases in synovial fluid of juvenile idiopathic arthritis patients. Correlation analysis of protease levels and HMGB1 levels in synovial fluid samples did not, however, reveal any direct relationship between the recorded levels. This study provides knowledge of proteolytic processing of HMGB1 relevant for the regulation of HMGB1 during inflammatory disease.
Copyright © 2020 Sowinska, Rensing, Klevenvall, Neog, Lundbäck and Harris.

Entities:  

Keywords:  cathepsin G; high mobility group box 1; juvenile idiopathic arthritis; matrix metalloproteinase-3; neutrophil elastase; proteolytic cleavage

Mesh:

Substances:

Year:  2020        PMID: 33391251      PMCID: PMC7772184          DOI: 10.3389/fimmu.2020.448262

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  36 in total

1.  Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models.

Authors:  Hanna Schierbeck; Peter Lundbäck; Karin Palmblad; Lena Klevenvall; Helena Erlandsson-Harris; Ulf Andersson; Lars Ottosson
Journal:  Mol Med       Date:  2011-06-07       Impact factor: 6.354

Review 2.  High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells.

Authors:  Ulf Andersson; Huan Yang; Helena Harris
Journal:  Semin Immunol       Date:  2018-03-09       Impact factor: 11.130

3.  The HMGB1 C-Terminal Tail Regulates DNA Bending.

Authors:  Rebecca H Blair; Abigail E Horn; Yogitha Pazhani; Lizbeth Grado; James A Goodrich; Jennifer F Kugel
Journal:  J Mol Biol       Date:  2016-08-21       Impact factor: 5.469

4.  The haptoglobin beta subunit sequesters HMGB1 toxicity in sterile and infectious inflammation.

Authors:  H Yang; H Wang; Y Wang; M Addorisio; J Li; M J Postiglione; S S Chavan; Y Al-Abed; D J Antoine; U Andersson; K J Tracey
Journal:  J Intern Med       Date:  2017-05-31       Impact factor: 8.989

Review 5.  HMGB1 is a therapeutic target for sterile inflammation and infection.

Authors:  Ulf Andersson; Kevin J Tracey
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

6.  High mobility group box protein 1-A prognostic marker for structural joint damage in 10-year follow-up of patients with juvenile idiopathic arthritis.

Authors:  Rille Pullerits; Hanna Schierbeck; Karin Uibo; Hille Liivamägi; Sirje Tarraste; Tiina Talvik; Erik Sundberg; Chris Pruunsild
Journal:  Semin Arthritis Rheum       Date:  2016-08-26       Impact factor: 5.532

7.  In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Shigekiyo Matsumoto; Akira Hasegawa; Norihisa Yasuda; Takayuki Noguchi
Journal:  Shock       Date:  2010-03       Impact factor: 3.454

8.  Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats.

Authors:  Keyue Liu; Shuji Mori; Hideo K Takahashi; Yasuko Tomono; Hidenori Wake; Toru Kanke; Yasuharu Sato; Norihito Hiraga; Naoto Adachi; Tadashi Yoshino; Masahiro Nishibori
Journal:  FASEB J       Date:  2007-07-12       Impact factor: 5.191

9.  Ligation of free HMGB1 to TLR2 in the absence of ligand is negatively regulated by the C-terminal tail domain.

Authors:  Hannah Aucott; Agnieszka Sowinska; Helena Erlandsson Harris; Peter Lundback
Journal:  Mol Med       Date:  2018-05-04       Impact factor: 6.354

10.  The long acidic tail of high mobility group box 1 (HMGB1) protein forms an extended and flexible structure that interacts with specific residues within and between the HMG boxes.

Authors:  Stefan Knapp; Susanne Müller; Giuseppe Digilio; Tiziana Bonaldi; Marco E Bianchi; Giovanna Musco
Journal:  Biochemistry       Date:  2004-09-28       Impact factor: 3.162

View more
  4 in total

Review 1.  The Effect and Regulatory Mechanism of High Mobility Group Box-1 Protein on Immune Cells in Inflammatory Diseases.

Authors:  Yun Ge; Man Huang; Yong-Ming Yao
Journal:  Cells       Date:  2021-04-28       Impact factor: 6.600

2.  Antileukemic Natural Product Induced Both Apoptotic and Pyroptotic Programmed Cell Death and Differentiation Effect.

Authors:  Wohn-Jenn Leu; Hsun-Shuo Chang; Ih-Sheng Chen; Jih-Hwa Guh; She-Hung Chan
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 3.  The Role of HMGB1 in Rheumatic Diseases.

Authors:  Yuanji Dong; Bingxia Ming; Lingli Dong
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

4.  Role of Extracellular High-Mobility Group Box-1 as a Therapeutic Target of Gastric Cancer.

Authors:  Wataru Takaki; Hirotaka Konishi; Daiki Matsubara; Katsutoshi Shoda; Tomohiro Arita; Satoshi Kataoka; Jun Shibamoto; Hirotaka Furuke; Kazuya Takabatake; Hiroki Shimizu; Shuhei Komatsu; Atsushi Shiozaki; Takeshi Kubota; Kazuma Okamoto; Eigo Otsuji
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.